Study on Retatrutide for Obesity and CVD Completes Evaluation | Retatrutide News

A study on retatrutide for obesity and cardiovascular disease has been completed. The trial was conducted over 113 weeks to evaluate efficacy and safety.
Clinical Trials · October 11, 2026